Out today #ESMO24! In the non-randomised phase 3b/4 #DESTINY-Breast12 study, #TrastuzumabDeruxtecan (T-DXd) treatment of patients with HER2-positive advanced breast cancer and active or stable #BrainMetastases shows consistent intracranial activity and systemic efficacy of T-DXd. Research by Nadia Harbeck, Nancy Lin et al https://lnkd.in/ehTTtXr3
Chair of Breast Cancer Surgery @ London Breast Institute | Consultant Oncoplastic Breast Surgeon | Princess Grace Hospital | Consultant Oncoplastic Breast Surgeon at St George’s University Hospitals NHS Foundation (2010)
Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT. The HR was 0.80 [95% CI 0.63 to 1.00] in the node-positive cohort and 0.99 [95% CI, 0.64 to 1.55] in the node-negative cohort. This is aligned with current guidelines. The benefit was primarily related to iDFS with no improvement in overall survival.
At #SABCS24, a phase 2 trial showed #ctDNA detection in HR+ early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy. #bcsm https://lnkd.in/epADPiCF
Physician-Scientist | Lasker Clinical Scholar | Distinguished Scholar | Head, Laboratory of Molecular Radiotherapy | Personal Account
Nice study demonstrating the potential repurposing of available #radiopharmaceuticals for new cancer types. Here, Ga-DOTATATE is shows positivity in a subset of patients with breast cancer (30%), which may benefit from SSTR-targeted therapy! https://lnkd.in/gY_4T-r3
Medical Director | Clinical Development | Medical Affairs Leadership | Global & Regional experience in Oncology, Hematology, Neurology, Rare Disease
🚀 Advancing Breast Cancer Treatment: The Power of MammaPrint 🚀 🔍 The study by @Agendia and led by @DrWilliamAudeh addresses a critical need in breast cancer care—identifying biomarkers that predict chemotherapy benefit for patients with HR+HER2- early-stage breast cancer. MammaPrint, a 70-gene signature, plays a key role in determining the risk of distant recurrence and predicting response to both adjuvant and neoadjuvant chemotherapy. 🧬 Key Findings: ✅Chemotherapy Sensitivity: Patients with higher MammaPrint risk indices (H1 and H2) showed a significant increase in pathological complete response (pCR) to neoadjuvant chemotherapy, with up to 30% achieving pCR in the highest risk category (H2). This underscores the test's utility in identifying those who are most likely to benefit from chemotherapy. ✅5-Year Follow-Up: The study also highlights how MammaPrint effectively predicts 5-year distant recurrence (DR) risk. For patients treated with endocrine therapy (ET) alone, the risk increased with higher MammaPrint indices. In contrast, chemotherapy showed a substantial benefit for high-risk patients, with a 2-16% absolute risk reduction depending on the risk category. 🔗 Conclusions: MammaPrint is a valuable tool for guiding treatment decisions, particularly in tailoring chemotherapy for patients with HR+HER2- early-stage breast cancer. By predicting which patients will derive significant benefit from chemotherapy, MammaPrint helps optimize personalized treatment plans, improving overall patient outcomes. 🌟 Implications: This research reinforces the importance of genomic testing in oncology, paving the way for more precise and effective cancer treatment strategies. #BreastCancerResearch #Oncology #MammaPrint #H1 #H2 #pCR #DR #CancerTreatment #PrecisionMedicine #ET #PatientCare #GenomicTesting #OncologyInnovation #PersonalizedMedicine #CancerResearch #MiamiBreast2024 @Agendia @DrWilliamAudeh
Recent research presented at #MiamiBreast2024 showcases the predictive power of MammaPrint in determining chemotherapy benefit for HR+HER2- early-stage breast cancer patients. The study, led by Agendia CMO, Dr. William Audeh and the FLEX Investigators’ Group, reveal that MammaPrint can predict which patients are more likely to benefit from chemotherapy. This research underscores the utility of MammaPrint in optimizing treatment plans and improving patient care. View the Poster: https://lnkd.in/gZx3dQTP #BreastCancerResearch #MammaPrint
Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis. #bcsm https://lnkd.in/eNfmvYgc
New WCLC article from memo! 𝗥𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 Read about the latest results from: - NeoCOAST-2 - KEYNOTE-671 - ALINA The full memo inOncology WCLC 2024 SPECIAL ISSUE is coming soon! #WCLC2024 #LungCancer #Research
CDK4/6 in combination with radiation for bone metastases in breast cancer patients is safe https://lnkd.in/dZTpBdkC
The NEOpredict-Lung study represents an importantevolution in the treatment of resectable NSCLC - Iván R González OncoAlert Lung Cancer Foundation of America Nina Maouelainin, DO, FCCP, MBA Nirmal Raut #Cancer #OncologyCenter #Hospital #NSCLC #OncoDaily #Oncology #ImmunePathways
Recent research presented at #MiamiBreast2024 showcases the predictive power of MammaPrint in determining chemotherapy benefit for HR+HER2- early-stage breast cancer patients. The study, led by Agendia CMO, Dr. William Audeh and the FLEX Investigators’ Group, reveal that MammaPrint can predict which patients are more likely to benefit from chemotherapy. This research underscores the utility of MammaPrint in optimizing treatment plans and improving patient care. View the Poster: https://lnkd.in/gZx3dQTP #BreastCancerResearch #MammaPrint
